<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82309">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01909648</url>
  </required_header>
  <id_info>
    <org_study_id>S55709</org_study_id>
    <secondary_id>S55709</secondary_id>
    <nct_id>NCT01909648</nct_id>
  </id_info>
  <brief_title>HbA2 Leuven and Its Impact on HbA1c Results</brief_title>
  <acronym>HbA2 Leuven</acronym>
  <official_title>HbA2 Leuven and Its Impact on HbA1c Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to demonstrate HbA2 Leuven mutation and to asssess its impact on
      routine HbA1c measurements.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Demonstration of presence/absence of HbA2 Leuven mutation</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstration of impact of HbA2 Leuven mutation on routine HbA1c measurements</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Family History HbA2 Leuven Mutation.</condition>
  <arm_group>
    <arm_group_label>HbA2 Leuven</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <arm_group_label>HbA2 Leuven</arm_group_label>
    <other_name>Impact of mutation on routine HbA1c measurements.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <arm_group_label>HbA2 Leuven</arm_group_label>
    <other_name>Demonstration of HbA2 Leuven mutation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Family history of HbA2 Leuven mutation.

        Exclusion Criteria:

          -  Any condition inhibiting simple blood withdrawal.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davy MJ Kieffer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter Gillard, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Koen Desmet, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
